Clinical Trial Update: Safety & Efficacy Study of ORGN001 (Formerly ALXN1101) in Pediatric Patients With MoCD Type A Currently Treated With rcPMP [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on ORGN001 (formerly ALXN1101) in pediatric MoCD Type A patients on rcPMP, completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Molybdenum Cofactor Deficiency Type

Drugs mentioned

• ORGN001 (formerly ALXN1101)

Snippet

Sponsor: Origin Biosciences | Conditions: Molybdenum Cofactor Deficiency, Type A | Phase 2 | Status: COMPLETED | Results posted: 2023-10-17